Sonnet BioTherapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch SONN and buy or sell other stocks, ETFs, and their options commission-free!About SONN
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
CEOPankaj Mohan
CEOPankaj Mohan
Employees12
Employees12
HeadquartersPrinceton, New Jersey
HeadquartersPrinceton, New Jersey
Founded2011
Founded2011
Employees12
Employees12
SONN Key Statistics
Market cap6.56M
Market cap6.56M
Price-Earnings ratio-1.88
Price-Earnings ratio-1.88
Dividend yield—
Dividend yield—
Average volume104.32K
Average volume104.32K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$2.97
52 Week high$2.97
52 Week low$0.6239
52 Week low$0.6239
Stock Snapshot
As of today, Sonnet BioTherapeutics(SONN) shares are valued at $1.26. The company's market cap stands at 6.56M, with a P/E ratio of -1.88.
Sonnet BioTherapeutics(SONN) stock opened on 2026-01-07 at —. The price climbed to — and dipped to —.
The Sonnet BioTherapeutics(SONN)'s current trading volume is 0, compared to an average daily volume of 104.32K.
In the last year, Sonnet BioTherapeutics(SONN) shares hit a 52-week high of $2.97 and a 52-week low of $0.62.
In the last year, Sonnet BioTherapeutics(SONN) shares hit a 52-week high of $2.97 and a 52-week low of $0.62.
People also own
Based on the portfolios of people who own SONN. This list is generated using Robinhood data, and it’s not a recommendation.